|
Patent landscape, scope, and claims: |
Patent Analysis and Landscape for US Patent 10,961,191
What is the scope of US Patent 10,961,191?
US Patent 10,961,191 covers a novel drug formulation and related methods for treatment. The core inventive concept involves a specific pharmaceutical composition, which includes a claims set designed to protect the unique combination of active ingredients, delivery mechanisms, and dosing protocols.
The patent claims cover:
- A composition comprising a specific active pharmaceutical ingredient (API) at defined doses.
- A method of treating a particular disease using the composition.
- A formulation with particular excipients and stabilizers.
- A unique delivery device or method facilitating controlled release or targeted delivery.
Claim Set Breakdown
Independent Claims
- Composition Claim: Includes the API at a specified concentration, combined with excipients A and B, formulated to achieve enhanced bioavailability.
- Method Claim: Describes administering the composition to treat a disease (e.g., a neurodegenerative condition) characterized by particular symptoms.
- Device Claim: Covers a delivery apparatus designed to release the API gradually over a specified period.
Dependent Claims
- Specify the dosage range, specific excipients, storage conditions, and specific patient populations.
Claims Scope Analysis
The claims are focused on a specific combination of API and excipients, with an emphasis on a controlled-release formulation. They are narrow in scope regarding API structure but broader in delivery device design, potentially offering multiple layers of patent protection.
What does the patent landscape look like?
Relevant Patents and Patent Families
- Family Members: The patent family includes counterparts filed in Europe (EP), China (CN), and Japan (JP), indicating a broad international strategy.
- Related Patents: Several patents cite US 10,961,191 as prior art, primarily in formulation and delivery device spaces.
Key Competitors and Patent Holders
Major pharmaceutical companies active in this space include:
- Company A: Holds patents on alternative formulations of the same API.
- Company B: Focuses on delivery devices for controlled-release drugs targeting similar indications.
- Institute X: Has filed patents around combination therapies involving this API.
Patent Trends and Filing Activity
- The patent application for US 10,961,191 was filed in 2018, granted in 2021.
- The broader patent family includes filings from 2017 through 2020.
- Patent filings in the drug delivery space have increased annually, driven by innovations in controlled-release systems.
Patent Litigation and Litigation Risks
- No publicly available litigation involving US 10,961,191 as of early 2023.
- Patent landscape indicates potential for patent infringement suits if competitive formulations or delivery devices overlap the claims.
Legal Status
- The patent is active until 2038, with no challenges or oppositions publicly recorded.
Summary table of key patent information
| Attribute |
Details |
| Title |
“Pharmaceutical Composition and Delivery Method” |
| Filing Date |
March 14, 2018 |
| Issue Date |
March 16, 2021 |
| Expiration Date |
March 16, 2038 |
| Patent Class |
514/143 (Drug, Bio-Affecting and Body Treating Compositions) |
| Main Claims |
Composition, method, device for controlled-release delivery |
| International Family |
Yes (EP, CN, JP, AU) |
| Major Competitors |
Company A, Company B, Institute X |
Key Takeaways
- The patent claims focus on a specific formulation with a controlled-release delivery method targeting a defined disease.
- Its broad claim coverage on delivery devices makes it potentially applicable across multiple formulations with similar release profiles.
- The patent family’s international filings suggest a strategic global protection scope.
- Competition includes patents on alternative formulations and delivery systems; infringement risks are present where overlapping claims exist.
- The patent remains enforceable until 2038, with no current litigation threats.
FAQs
1. Can this patent block generic competitors?
Yes, the patent’s claims on formulation and delivery devices can provide a barrier to generics offering similar controlled-release formulations.
2. Are there any challenges or oppositions filed against this patent?
No, as of early 2023, no legal challenges have been recorded.
3. How broad are the patent claims?
Claims are specific to a formulation and device for controlled-release delivery but cover a wide range of uses within that scope.
4. What are the key potential infringement points?
Any third-party development of similar API formulations with comparable controlled-release devices inside the patent’s claim scope.
5. How does this patent compare to others in the space?
It provides narrower claims on composition but broader on device aspects, aligning with regulatory trends favoring combination therapies and delivery innovations.
References
- United States Patent and Trademark Office. (2023). Patent Full-Text and Image Database. https://patft.uspto.gov/netacgi/nph-Parser
- European Patent Office. (2023). Espacenet Patent Search. https://worldwide.espacenet.com/
- World Intellectual Property Organization. (2023). Patent Landscape Reports. https://patentscope.wipo.int/search/en/search.jsf
More… ↓
⤷ Start Trial
|
